KinoPharma, Inc.

- Development of a novel antiviral drug against human papillomavirus - KinoPharma, Inc. (KinoPharma) and IWAKI SEIYAKU CO., LTD. (IWAKI SEIYAKU) have jointly commenced a Phase 2 clinical trial to confirm the efficacy of a drug candidate for the treatment of cutaneous warts ('the Drug') in humans. Development background KinoPharma and IWAKI SEIYAKU have been jointly developing an ointment since January 2021 based on KinoPharma's novel antiviral agent against human papillomavirus (HPV). This collaboration was further developed and a co-development and commercialization agreement was signed in August 2022 to advance clinical development for the indication of cutaneous warts. After confirming the safety of the Drug in animals and humans, the decision was made jointly to commence a Phase 2 clinical trial to confirm the efficacy of the Drug against cutaneous warts, and a notification of clinical trial (CTN) was submitted to the Pharmaceuticals and Medical Devices Agency (PMDA) today. About the Drug Based on KinoPharma's novel concept of human papillomavirus (HPV) antiviral drugs targeting human host factors, KinoPharma and IWAKI SEIYAKU have collaborated to develop an ointment formulation that is the optimal delivery method for HPV infection on the skin and mucous membranes, and have filed a patent application. What is human papillomavirus (HPV)? It is so named because it forms a raised papilla-like tumor when it infects the skin or other parts of the body. There are more than 100 different types of HPV, some of which may lead to cancer and others to benign neoplasms. HPV infection is known to cause a number of diseases such as skin (cutaneous warts), anogenital (condyloma acuminatum, anal cancer), reproductive organ (cervical cancer) and upper aerodigestive tract (oropharyngeal cancer, etc.) infections. What are cutaneous warts? Cutaneous warts are small proliferative lesions (benign tumors) of the skin caused by infection with the human papillomavirus (HPV). HPV enters the skin through small wounds and infects cells in the basal layer of the epidermis. Infected cells actively divide and form warts. Treatment generally involves cryotherapy using liquid nitrogen, but there are problems such as the need for repeated procedures and pain associated with the treatment. There are no approved antiviral drugs for HPV. Cutaneous warts are relatively common in children, but can occur in all age groups, with an estimated prevalence of 3.4% (based on data from the 2021 Japan Social Insurance Medical Practice Survey). ――――――――――――――――――――――――――――――――――――――――――――― About IWAKI SEIYAKU CO., LTD. IWAKI SEIYAKU is a pharmaceutical company focused on the manufacture and distribution of the ethical, OTC medicines, and Aesthetic products. The company is especially active in the dermatology market. IWAKI SEIYAKU is expanding its brand and product portfolio in the future and will make every effort to supply this product stably. About KinoPharma, Inc. KinoPharma is a biotech engaged in research and development of novel antivirals in collaboration with Kyoto University and other top universities in Japan. It is involved in the development of new concept antiviral drugs that suppress viral replication by targeting host factors. In addition to HPV-related diseases, KinoPharma is also working on the development of drugs for deadly viral infections and next-generation pandemic viral infections. ――――――――――――――――――――――――――――――――――――――――――――― Contact Business Administration Dept., KinoPharma, Inc. E-mail：info@kinopharma.com HP：

Dublin, May 10, 2021 (GLOBE NEWSWIRE) -- The "Cervical Dysplasia Market Share, Size, Trends, Industry Analysis Report, By Type; By End-Use, By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering. The global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study. The report gives a detailed insight into current market dynamics and provides analysis on future market growth.The rising prevalence of cervical cancer and awareness regarding its early diagnosis is the key cervical dysplasia industry impacting factors. As per the report published by World Health Organization, in 2018, worldwide there were around 5, 70,000 new cases of cervical cancer, and more than 3,11,000 deaths were recorded. It also reported that HPV is the most common causal factor for cervical dysplasia among women.Moreover, Cervical Awareness Month was introduced by the U.S. Congress, in 2019, to declare the month of January dedicated to the patients suffering from cervical cancer in the market. National Cervical Cancer Coalition under government control was responsible to highlight issues related to disease and the importance of early diagnosis. These government-supported initiatives are bound to increase awareness regarding disease screening and are anticipated to boost the market growth for cervical dysplasia.Market participants such as Qiagen N.V., Abbott Laboratories, Hologic, Inc., Quest Diagnostics, DYSIS Medical Ltd, Micromedic Technologies Ltd., OncoHealth Corporation, Inc., CooperSurgical Inc., and Roche are some of the key players operating in the global market for cervical dysplasia. The companies in the marketplace for cervical dysplasia are focussing on collaborations and agreement to survive in the highly regulated market with huge patient unmet needs.For instance, in January 2020, both Japan pharmaceutical giants ASKA Pharmaceutical and KinoPharma entered into a collaborative agreement for the development and commercialization of drug candidates for cervical dysplasia in the market, which is under preclinical phase under KinoPharma. Under the agreement, ASKA would obtain exclusive rights to sell the drug in the Japanese market and will help later in co-developing potential drug candidates and KinoPharma in return will receive upfront payments for the exclusive licensing.Earlier, in July 2019, Roche expanded its portfolio of offerings under the Global Access Program to include HPV, and Mycobacterium tuberculosis diagnostic products for the emerging countries, particularly in countries where the prevalence of HPV is highest. This expansion is an attempt towards cost-effective treatments for cervical dysplasia in resource constraint countries and to implement multiple large-scale programs.The publisher has segmented the cervical dysplasia market report on the basis of type, end-use, and region:Cervical Dysplasia, by Type Outlook Cervical Dysplasia, by End-Use Outlook Cervical Dysplasia, by Regional Outlook Key Topics Covered: 1. Introduction1.1. Report Description1.2. Stakeholders2. Executive Summary2.1. Market Highlights3. Research Methodology3.1. Overview3.2. Data Sources4. Cervical Dysplasia Market Insights4.1. Cervical Dysplasia - Industry snapshot4.2. Cervical Dysplasia Market Dynamics4.3. Porter's Five Forces Analysis4.4. PESTLE Analysis4.5. Cervical Dysplasia Market Industry trends5. Cervical Dysplasia Market Assessment by Type5.1. Key Findings5.2. Introduction5.3. Diagnostic Tests5.4. Diagnostic Devices5.5. Colposcope6. Global Cervical Dysplasia Market, by End-Use6.1. Key Findings6.2. Introduction6.3. Hospitals6.4. Diagnostic Centers6.5. Ambulatory Surgical Centers7. Cervical Dysplasia Market Assessment by Geography7.1. Key findings7.2. Introduction7.3. Cervical Dysplasia Market - North America7.4. Cervical Dysplasia Market - Europe7.5. Cervical Dysplasia Market - Asia-Pacific7.6. Cervical Dysplasia Market - Middle East & Africa7.7. Cervical Dysplasia Market - Latin America8. Competitive Landscape8.1. Expansion and Acquisition Analysis8.2. Partnerships/Collaborations/Agreements/Exhibitions9. Company Profiles9.1. Qiagen N.V.9.2. Abbott Laboratories9.3. Hologic, Inc.9.4. Quest Diagnostics9.5. DYSIS Medical Ltd.9.6. Micromedic Technologies Ltd.9.7. OncoHealth Corporation, Inc.9.8. CooperSurgical Inc.9.9. Roche9.10. Karl Kaps GmbH & Co. KG For more information about this report visit